Cognitive behavior therapy in medication non-responders with obsessive–compulsive disorder: A prospective 1-year follow-up study

Abramowitz, 1997, Effectiveness of psychological and pharmacological treatments for obsessive–compulsive disorder: a quantitative review, Journal of Consulting and Clinical Psychology, 65, 44, 10.1037/0022-006X.65.1.44 Abramowitz, 2006, The Psychological treatment of obsessive–compulsive disorder, Canadian Journal of Psychiatry, 51, 407, 10.1177/070674370605100702 Ackerman, 1994, Predictors of treatment response in obsessive compulsive disorder: Multivariate analyses from a multicenter trial of clomipramine, Journal of Clinical Psychopharmacology, 14, 247, 10.1097/00004714-199408000-00004 American Psychiatric Association, 1994 Dew, 2006, Rating scales for mood disorders, 69 Eddy, 2004, A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive–compulsive disorder, Clinical Psychology Review, 24, 1011, 10.1016/j.cpr.2004.08.004 Endicott, 2010, Global Assessment of Functioning (GAF) scale, 86 First, 1995 First, 1997 Fisher, 2005, How effective are cognitive and behavioral treatments for obsessive–compulsive disorder? A clinical significance analysis, Behavior Research Therapy, 43, 1543, 10.1016/j.brat.2004.11.007 Foa, 2005, Randomized placebo controlled trial of exposure and ritual prevention, clomipramine and their combination in the treatment of obsessive compulsive disorder, American Journal of Psychiatry, 162, 151, 10.1176/appi.ajp.162.1.151 Gava, 2007, Psychological treatments versus treatment as usual for obsessive compulsive disorder (OCD), Cochrane Database Systematic Review, 18, CD005333 Goodman, 1989, The Yale-Brown Obsessive Compulsive Scale II: validity, Archives of General Psychiatry, 46, 1012, 10.1001/archpsyc.1989.01810110054008 Goodman, 1989, The Yale-Brown Obsessive Compulsive Scale I: development, use, and reliability, Archives of General Psychiatry, 46, 1006, 10.1001/archpsyc.1989.01810110048007 Greist, 1995, Efficacy and tolerability of serotonin transport inhibitors in obsessive–compulsive disorder: a meta analysis, Archives of General Psychiatry, 52, 53, 10.1001/archpsyc.1995.03950130053006 Guy, 2010, Clinical Global Impressions (CGI) scale, 90 Guy, 1976 Horwath, 2000, The epidemiology and cross-national presentation of obsessive compulsive disorder, Psychiatric Clinics of North America, 23, 493, 10.1016/S0193-953X(05)70176-3 Jacobson, 1991, Clinical significance: a statistical approach to defining meaningful change in psychotherapy research, Journal of Consulting and Clinical Psychology, 59, 12, 10.1037/0022-006X.59.1.12 Kampman, 2002, Addition of cognitive behaviour therapy for obsessive–compulsive disorder patients non-responding to fluoxetine, Acta Psychiatrica Scandinavia, 106, 314, 10.1034/j.1600-0447.2002.01261.x Koran, 2007 Kozak, 1997 Kozak, 2000, Cognitive behavior therapy and pharmacotherapy for OCD, 501 Lobbestael, J., Leurgans, M., & Arntz, A. (2010). Inter-rater reliability of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID I) and Axis II Disorders (SCID II). Clinical Psychology and Psychotherapy (March 21). Mancebo, 2006, The Brown Longitudinal Obsessive Compulsive Study: treatments received and patient impressions of improvement, Journal of Clinical Psychiatry, 67, 1713, 10.4088/JCP.v67n1107 March, 1997, The expert consensus guideline series: treatment of obsessive–compulsive disorder, Journal of Clinical Psychiatry, 58, 3 Marks, 1997, Behaviour therapy for obsessive–compulsive disorder: a decade of progress, Canadian Journal of Psychiatry, 42, 1021, 10.1177/070674379704201002 Miguel, 2005, Obsessive–compulsive disorder phenotypes: implications for genetic studies, Molecular Psychiatry, 10, 258, 10.1038/sj.mp.4001617 Montgomery, 1979, A new depression scale designed to be sensitive to change, British Journal of Psychiatry, 134, 382, 10.1192/bjp.134.4.382 National Institute for Health and Clinical Excellence. (2005). Obsessive compulsive disorder: core interventions in the treatment of obsessive–compulsive disorder and body dysmorphic disorder [NICE Guideline]. Clinical guideline No. 31. London, UK: National Institute for Health and Clinical Excellence. Pallanti, 2002, Treatment non-response in OCD: methodological issues and operational definitions, International Journal Neuro Psychopharmacology, 5, 181 Pallanti, 2004, A qualitative analysis of nonresponse: management of treatment refractory obsessive–compulsive disorder, Journal of Clinical Psychiatry, 65, 6 Patterson, 1995, Field trial of the Global Assessment of Functioning Scale—modified, American Journal of Psychiatry, 152, 1386, 10.1176/ajp.152.9.1386 Pigott, 1998, Biological treatments for obsessive–compulsive disorder: literature review, 298 Pigott, 1999, A review of the efficacy of selective serotonin reuptake inhibitors in obsessive–compulsive disorder, Journal of Clinical Psychiatry, 60, 101, 10.4088/JCP.v60n0206 Primakoff, 1986, Homework compliance: an uncontrolled variable in cognitive therapy outcome research, Behavior Therapy, 17, 433, 10.1016/S0005-7894(86)80073-9 Rasmussen, 1993, Current issues in pharmacological management of obsessive–compulsive disorder, Journal of Clinical Psychiatry, 54, 4 Rauch, 1998, Pharmacological treatment of obsessive compulsive disorder, 358 Schwartz, 1996 Schwartz, 1998, Neuroanatomical aspects of cognitive behavioral therapy response in obsessive–compulsive disorder: an evolving perspective on brain and behavior, British Journal of Psychiatry, 173, 38, 10.1192/S0007125000297882 Shetti, 2005, Clinical predictors of drug nonresponse in obsessive–compulsive disorder, Journal of Clinical Psychiatry, 66, 1517, 10.4088/JCP.v66n1204 Simpson, 1999, Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive–compulsive disorder: an open trial, Journal of Clinical Psychiatry, 60, 584, 10.4088/JCP.v60n0904 Simpson, 2008, A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive–compulsive disorder, American Journal of Psychiatry, 165, 621, 10.1176/appi.ajp.2007.07091440 Skevington, 2004, The World Health Organization's WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group, Quality of Life Research, 13, 299, 10.1023/B:QURE.0000018486.91360.00 Spielberger, 1970 Spielberger, 2009, Assessment of emotion: anxiety, anger, depression and curiosity, Applied Psychology: Health and Well-being, 1, 271, 10.1111/j.1758-0854.2009.01017.x Tolin, 2007, A randomized controlled trial of self-directed versus therapist-directed cognitive-behavioral therapy for obsessive–compulsive disorder patients with prior medication trials, Behavior Therapy, 38, 179, 10.1016/j.beth.2006.07.001 Tolin, 2004, Cognitive-behavioral therapy for medication nonresponders with obsessive–compulsive disorder: a wait-list-controlled open trial, Journal of Clinical Psychiatry, 65, 922, 10.4088/JCP.v65n0708 Tundo, 2007, Addition of cognitive behavioral therapy for nonresponders to medication for obsessive compulsive disorder: a naturalistic study, Journal of Clinical Psychiatry, 68, 1552, 10.4088/JCP.v68n1013 Whittal, 2005, Treatment of obsessive–compulsive disorder: cognitive behavior therapy vs. exposure and response prevention, Behavior Research and Therapy, 43, 1559, 10.1016/j.brat.2004.11.012 World Health Organization (WHO), 1996 Zanarini, 2000, The Collaborative Longitudinal Personality Disorders Study: reliability of axis I and II diagnoses, Journal of Personality Disorders, 14, 291, 10.1521/pedi.2000.14.4.291